High lipoprotein(a) may explain one quarter of clinical familial hypercholesterolemia diagnoses in Danish lipid clinics.
Dutch Lipid Clinical Network Score
Familial hypercholesterolemia
Lipid Clinic
Lipoprotein(a)
Journal
The Journal of clinical endocrinology and metabolism
ISSN: 1945-7197
Titre abrégé: J Clin Endocrinol Metab
Pays: United States
ID NLM: 0375362
Informations de publication
Date de publication:
20 Oct 2023
20 Oct 2023
Historique:
received:
09
06
2023
revised:
13
10
2023
accepted:
17
10
2023
medline:
20
10
2023
pubmed:
20
10
2023
entrez:
20
10
2023
Statut:
aheadofprint
Résumé
Cholesterol carried in lipoprotein(a) adds to measured low-density lipoprotein cholesterol (LDL-C) and may therefore drive some diagnoses of clinical familial hypercholesterolemia (FH). We investigated plasma lipoprotein(a) in subjects referred to Danish lipid clinics and evaluated the impact of plasma lipoprotein(a) for a diagnosis of FH. Individuals referred to 15 Danish lipid clinics suspected of FH according to nationwide referral criteria were recruited between September 1st 2020 and November 30th 2021. All individuals were classified according to the Dutch Lipid Network criteria for FH before and after LDL-C was adjusted for 30% cholesterol content in lipoprotein(a). We calculated the fraction of individuals fulfilling a clinical diagnosis of FH partly due to elevated lipoprotein(a). We included a total of 1,166 individuals for analysis, of whom 206 fulfilled a clinical diagnosis of FH. Median lipoprotein(a) was 15 mg/dL (29 nmol/L) in those referred and 28% had lipoprotein(a) ≥50 mg/dL (105 nmol/L), while 2% had levels ≥180 mg/dL (389 nmol/L). We found that 27% (55/206) of those fulfilling a clinical diagnosis of FH was partly due to high lipoprotein(a). Elevated lipoprotein(a) was common in individuals referred to Danish lipid clinics and one quarter of individuals who fulfilled a clinical diagnosis of FH were partly due to elevated lipoprotein(a). These findings support the notion that the LPA gene should be considered an important causative gene in patients with clinical FH and further support the importance of measuring lipoprotein(a) when diagnosing FH as well as for stratification of cardiovascular risk.
Sections du résumé
BACKGROUND
BACKGROUND
Cholesterol carried in lipoprotein(a) adds to measured low-density lipoprotein cholesterol (LDL-C) and may therefore drive some diagnoses of clinical familial hypercholesterolemia (FH). We investigated plasma lipoprotein(a) in subjects referred to Danish lipid clinics and evaluated the impact of plasma lipoprotein(a) for a diagnosis of FH.
METHODS
METHODS
Individuals referred to 15 Danish lipid clinics suspected of FH according to nationwide referral criteria were recruited between September 1st 2020 and November 30th 2021. All individuals were classified according to the Dutch Lipid Network criteria for FH before and after LDL-C was adjusted for 30% cholesterol content in lipoprotein(a). We calculated the fraction of individuals fulfilling a clinical diagnosis of FH partly due to elevated lipoprotein(a).
RESULTS
RESULTS
We included a total of 1,166 individuals for analysis, of whom 206 fulfilled a clinical diagnosis of FH. Median lipoprotein(a) was 15 mg/dL (29 nmol/L) in those referred and 28% had lipoprotein(a) ≥50 mg/dL (105 nmol/L), while 2% had levels ≥180 mg/dL (389 nmol/L). We found that 27% (55/206) of those fulfilling a clinical diagnosis of FH was partly due to high lipoprotein(a).
CONCLUSIONS
CONCLUSIONS
Elevated lipoprotein(a) was common in individuals referred to Danish lipid clinics and one quarter of individuals who fulfilled a clinical diagnosis of FH were partly due to elevated lipoprotein(a). These findings support the notion that the LPA gene should be considered an important causative gene in patients with clinical FH and further support the importance of measuring lipoprotein(a) when diagnosing FH as well as for stratification of cardiovascular risk.
Identifiants
pubmed: 37862146
pii: 7325785
doi: 10.1210/clinem/dgad625
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.